Corcept Therapeutics Faces Class Action Lawsuit After 50% Stock Plunge

Corcept Therapeutics (CORT) and its top executives are facing a securities class action lawsuit following a massive 50% decline in the company's stock price. The litigation alleges that Corcept misled investors by ignoring repeated warnings from the FDA regarding its New Drug Application (NDA) for Relacorilant. According to the filing, the company failed to disclose significant "evidence gaps" in its clinical data, which eventually led to the sharp market sell-off. The lawsuit claims that management's actions caused substantial financial harm to shareholders who purchased the stock at artificially inflated prices. Investors have until April 21, 2026, to move for lead plaintiff status in the ongoing legal proceedings. This development adds significant regulatory and legal pressure to the biotechnology firm's outlook and market valuation.